We’re excited to share that Biocytogen will attend the 7th Ace Drug Discovery Summit in San Diego, CA, from May 6th - 7th. This premier forum will unite over 120 leaders from biotech and pharma to explore emerging technologies and best practices across drug discovery. Come meet our team at booth 06 to discover how Biocytogen’s specialized mouse models and CRISPR/Cas9-based gene editing services can accelerate your drug discovery journey!
What is the 7th Ace Drug Discovery Summit?
The 7th Ace Drug Discovery Summit will highlight the latest breakthroughs in AI-driven drug design, CAR-T cell therapies, and the future landscape of pharmaceutical research. It will feature interactive discussion panels, exclusive meetings, and innovative presentations, allowing attendees to gain actionable insights and collaborate on purposeful projects.
Event Overview
Date: May 6th - 7th, 2026
Venue: Courtyard by Marriott San Diego Mission Valley/Hotel Circle, 595 Hotel Cir S, San Diego, CA 92108
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
Let’s transform the future of drug discovery together, we look forward to meeting you in San Diego, CA!
